Krazati Adagrasib KRAS G12C Inhibitor NSCLC Clinical Review 2026
Author: Critical Kare PharmaPrecision Oncology Desk
On October 18, 2026, thoracic oncology panels highlighted Krazati® (Adagrasib 200 mg film-coated tablets) developed by Mirati Therapeutics / Bristol Myers Squibb as a potent, CNS-penetrant covalent KRAS G12C inhibitor.
Engineered for sustained target inhibition with a 23-hour elimination half-life and dose-dependent blood-brain barrier penetrance, Krazati delivers durable systemic disease control and significant intracranial objective responses in advanced NSCLC.
Through Critical Kare Pharma, verified original manufacturer supplies of Krazati Adagrasib 200mg Tablets are provided to hospital oncology departments globally.
The KRYSTAL-1 Phase 2/3 Benchmarks
- Confirmed ORR & Disease Control: Achieved a 43% objective response rate with an 80% disease control rate in patients with KRAS G12C-mutated NSCLC previously treated with platinum chemotherapy and anti-PD-(L)1 therapy.
- Intracranial Activity: 42% confirmed intracranial objective response rate in patients with active untreated brain metastases.
- Dosing: Standard dosage is 600 mg orally twice daily (three 200 mg tablets twice daily) taken with or without food.
Global Named-Patient Delivery
Coordinated under official regulatory import frameworks reaching patient doorsteps and clinics in 4–8 business days worldwide.
